Funding Opportunities

Grants for melanoma and skin cancer clinical research

Melanoma and Skin Cancer Trials conducts investigator-initiated clinical trials and related research to improve how doctors prevent, diagnose and treat melanoma and skin cancer.

We have built an impressive reputation for delivering multicentre trials that improve melanoma and skin cancer outcomes across the world. Since 1999, we have delivered 29 clinical trials involving over 7,500 participants.

Melanoma and Skin Cancer Trials facilitates the development of competitive investigator-initiated proposals through our concept development pathway. For more information on how we can help you develop a research proposal and secure funding, contact us.

2026 GSK Award for Research Excellence

Open Date

10 March 2026

Closing Date

1 May 2026

Grant amount

$150,000 AUD

Application website

2026 GSK ARE Nominations

About

The GSK Award for Research Excellence (ARE) is one of the most prestigious and longstanding awards available to the Australian medical research community. Among the previous recipients of the GSK Award for Research Excellence are some of Australia’s most noted scientific researchers, including Professor Tony Basten (1980), Dr Bruce Kemp (1993), Professor Kathryn North (2011), and Professors Georgina Long and Richard Scolyer (2018).

Since 1980, the annual GSK ARE has been awarded to individuals or two-person teams with very significant existing track records who are well placed to further their contributions in the near future. A $150,000 grant to the winner(s)’ institution supports this goal.

The judging criteria are weighted as follows:

50% – potential for the nominee’s contribution to science to directly or indirectly lead to the improvement of human health

30% – potential for the nominee to continue to make research contributions in the field of human health. Impact on people’s lives as a result of their work and/or potential translation to a person(s) experience in the health system if their work didn’t exist/progress

20% – nominee’s accomplishments based on academic and employment record, research grants and awards received, cited publications, and other examples of research productivity

2026 Australian Melanoma Research Foundation (AMRF) Research Grants

Open Date

12 January 2026

Closing Date

30 April 2026 (EOI); 25 May 2026 (Full Application)

Grant amount

$20,000 AUD

Application website

2026 AMRF Research Grants

About

The aim of the AMRF’s grants scheme is to support high quality research that is not fully funded through other grant schemes or from other sources. AMRF funds are to be applied to offset the direct costs of the research.

The proposed research may be part of an existing research program. However, the application to the AMRF should be for a stand-alone component of that existing project.

AMRF will specifically focus on the support of the next generation of melanoma researchers in Australia by providing research grants to post-graduate students (up to $10,000) and early career researchers (up to $20,000).

2025 NHMRC-Horizon Europe - GO7886

Open Date

10 September 2025

Closing Date

29 April 2026 (Single stage deadline model); 25 Nov 2026 (Two-stage deadline model)

Grant amount

$1,000,000.00 AUD (Total Amount $4,000,000.00 AUD)

Application website

2025 NHMRC-Horizon Europe

About

The 2025 NHMRC-Horizon Europe grant opportunity supports Australian participation in international collaborative research under Horizon Europe. Horizon Europe facilitates collaboration and strengthens research impact and innovation while tackling global challenges.

NHMRC will invite Australia-based researchers who are listed on eligible applications deemed fundable by the European Commission (EC) to apply to NHMRC for support of the Australian component of research under the following topics submitted under the Horizon Europe topics listed in section 2.4 of the 2025 NHMRC-Horizon Europe Guidelines.

Ideas Grants 2026 - GO8295

Open Date

11 March 2026

Closing Date

8 April 2026 (Minimum Data); 6 May 2026 (Full Application)

Grant amount

Total Amount $297,100,000.00 AUD

Application website

Ideas Grants 2026

About

The objective of the Ideas Grant scheme is to support innovative research projects addressing a specific question(s).

The expected outcomes are:

  • innovative and creative research
  • funding of researchers at all career stages
  • funding any area of health and medical research from discovery to implementation.

It is expected that the Chief Investigator A (CIA) will have the capability to lead the team in achieving the project aims.

The Ideas Grant scheme is not intended to support research where a clinical trial or cohort study is the primary objective. Applicants conducting projects which incorporate elements of clinical trial and/or cohort study must consider whether the project goals are more applicable to the Ideas Grant or Clinical Trials and Cohort Grant schemes.

Ramsay Hospital Research Foundation Translational Challenge Grant

Open Date

1 April 2026

Closing Date

13 May 2026

Grant amount

$400,000.00 AUD

Application website

RHRF Grants program

About

The Translational Challenge Grant (TCG) is the flagship program of the Ramsay Hospital Research Foundation, driving research that tackles the root causes of health inequality. By funding projects that explore the impact of education, socioeconomic status, lifestyle factors and environment, the TCG aims to break the cycle of disadvantage and create lasting improvements in patient outcomes.

A maximum of $400,000 is available per project.

Eligibility criteria
To be eligible to apply for the Translational Challenge Grant, projects must:

  • Be undertaken in one of the following clinical areas: cancer, mental health, cardiovascular disease, orthopaedic surgery or musculoskeletal injury. We will consider funding other clinical areas depending on the scope of the health impact in that area.
  • Demonstrate a commitment to improving social disadvantage by including one key social determinant of health.
  • Be undertaken at both a Ramsay site and a non-Ramsay site.
  • Include a diverse patient population and benefit patients in both private and public health care settings.

2026 Australian Cancer Research Foundation (ACRF) Annual Research Grant

Open Date

9 March 2026

Closing Date

22 May 2026

Grant amount

Total Amount $5,000,000.00 AUD

Application website

Australian Cancer Research Foundation

About

ACRF awards capital grants (between $1.5 to $5 million) for technology, equipment and infrastructure for cancer research at Australian medical research institutes, hospitals and universities.

Grant applications are open to research into all types of cancer with a research focus on detection, prevention, and/or treatment.

ACRF promotes collaboration amongst researchers and clinicians and encourages novel and innovative cancer research projects. All applications are competitively reviewed by the ACRF Medical Research Advisory Committee (MRAC) who recommend the best projects to the ACRF Board of Trustees for funding.

Grants-in-Aid

Open Date

20 April 2026

Closing Date

19 May 2026 (EOI); 1 September 2026 (Full Application)

Grant amount

$360,000 AUD

Application website

Cancer Council Victoria

About

Grants-in-Aid funds high quality research focused on discovering and improving prevention, detection, treatment, and care for people affected by cancer.

In the 2026 round, up to 12 grants will be available (maximum value $360,000 per grant).

  • 6 general grants (max. $120,000 p.a. for two or three years)
  • 1 mesothelioma grant (max. $120,000 p.a. for two or three years)
  • 1 non‑Hodgkin’s lymphoma grant (max. $120,000 p.a. for two or three years)
  • 4 clinical trial research grants (two- or three-year proposals, no p.a. funding cap)
    Priority area: People with disabilities and/or mental health conditions
    Priority area: Rare or less common cancers

MRFF 2026 National Critical Research Infrastructure - GO7982

Open Date

18 February 2026

Closing Date

14 July 2026

Grant amount

Total amount $85,000,000.00 AUD

Application website

National Critical Research Infrastructure

About

The 2026 National Critical Research Infrastructure initiative invests in research infrastructure to ensure Australian researchers find innovative solutions to complex health problems in areas of unmet medical need. This grant opportunity has four streams.

Stream 1 – Innovation enablers

Address an area of unmet medical need by promoting the development and implementation of new research infrastructure by supporting development and/or expansion of research enablers such as biobanks, tissue repositories, novel platforms, and secure health data environments to create valuable research resources.

Stream 2 – Digitisation of health care

Translate or implement innovative artificial intelligence technologies into health applications that:

  • benefit multiple health disciplines/areas
  • involve consumers in the research journey to ensure the research is applicable to the needs of the Australian community; and
  • increase artificial intelligence workforce capacity and capability, particularly in relation to health, through cross-sector and interdisciplinary collaboration.

Stream 3 – Co-investment partnerships

Utilise co-investment (cash only) with the research sector, state and/or territory governments, and industry, in significant critical research infrastructure (e.g. facilities, personnel and equipment):

  • to support development of research capacity, capability and/or effectiveness in an area of unmet medical need, or
  • to enable Australian research using new platforms, systems and services in an area of unmet medical need.

Stream 4 – mRNA technology enablers

Leverage and enhance emerging mRNA technologies, platforms, and/or equipment to accelerate development of mRNA-based vaccines and therapeutics in an area of unmet medical need.

An application may only be submitted to one of the above four streams. Applicants must specify the stream to which they are applying in their application.

MRFF 2026 Consumer-Led Research Grant Opportunity - GO8270

Open Date

4 March 2026

Closing Date

5 August 2026

Grant amount

$2,500,000.00 AUD (Total amount $20,000,000.00 AUD)

Application website

2026 Consumer-Led Research Grant

About

The objective of this grant opportunity is to provide grants of financial assistance to support medical research and medical innovation projects that:

Stream 1 (Incubator): identify health priorities, develop new approaches and/or methodologies and conduct pilot studies addressing health issues and/or barriers that:

  • are co-led, co-produced and/or co-designed with consumers
  • are in partnership with health services
  • increase consumers’ understanding of, and involvement in, research.

Stream 2 (Targeted Call for Research): develop and/or test scalable and sustainable approaches, in partnership with consumers, that enable self-care interventions or improve quality of life and/or survivorship care.

Approaches are for individuals from one or more priority populations, who have experienced or are experiencing long-term diseases and conditions. Approaches may, where appropriate, also deliver for the individual’s families, carers and communities.

Topic A: Research projects that focus on cancer
Topic B: Research projects that focus on long term physical diseases and conditions other than cancer
Topic C: Research projects that focus on mental health challenges, diseases or conditions.

MRFF 2026 Genomics Health Futures Grant Opportunity - GO8294

Open Date

18 March 2026

Closing Date

19 August 2026

Grant amount

$8,000,000.00 AUD (Total amount $74,000,000.00 AUD)

Application website

2026 Genomics Health Futures Grant Opportunity

About

The objective of this GO is to provide grants of financial assistance to support medical research and medical innovation projects that:

Stream 1 (TCR): develop genomic tools and technologies to identify genetic predisposition to cancer and improve screening and targeted intervention. Focus on increased access to genomic testing and on liquid biopsy.

Stream 2 (TCR): conduct scalable research to enhance novel gene discoveries, increase diagnostic rates and enable disease modelling to support development of targeted therapies or prevention strategies.

Stream 3 (Incubator): develop novel methods for using polygenic risk scores to identify subgroups of the population at high risk of common and complex diseases.

  • Topic A: Cardiovascular disease
  • Topic B: Diabetes
  • Topic C: Other common and/or complex diseases

Stream 4 (Incubator): develop novel methods for improving accuracy and usefulness of polygenic risk scores to stratify people with common cancers for surveillance and treatment.

  • Topic A: Breast Cancer
  • Topic B: Colorectal cancer
  • Topic C: Prostate cancer
  • Topic D: Other common cancers

Stream 5 (TCR): undertake research to enhance or streamline uptake of clinical genomics into practice.

Stream 6 (Accelerator): develop and maintain infrastructure to support research collaboration by enabling data sharing, portability, longevity and connectivity of analysis across Australia. Research conducted should address emerging ethical, legal and social issues associated with the governance of clinical and genomic datasets with particular focus on the application of advanced analytics (e.g. AI) to enhance the diagnostic utility of genomics.

Applicants must propose research that addresses these objectives and those of the Genomics Health Futures Mission as outlined in the Roadmap and Implementation Plan.

MRFF 2026 International Clinical Trial Collaborations Grant Opportunity - GO8232

Open Date

11 February 2026

Closing Date

16 September 2026

Grant amount

$3,000,000.00 AUD (Total Amount $13,000,000.00 AUD)

Application website

2026 International Clinical Trial Collaborations Grant

About

The Medical Research Future Fund (MRFF) Clinical Trials Activity Initiative (the Initiative) aims to increase clinical trial activity in Australia in order to improve the evidence base supporting clinical care and to help patients access trials relevant to their health circumstances and enable researchers to bring international trials to Australian patients. 

The objective of this grant opportunity is to provide grants of financial assistance to support medical research and medical innovation projects that: 

  • Promote Australian involvement in international collaborative investigator-initiated clinical trials research through the establishment and co-ordination of clinical trial site/s in Australia.
  • Provide high-quality evidence of the effectiveness of novel health treatments, drugs or devices in ‘usual care’ settings, which will support a decision on whether to deliver the intervention in an Australian setting.

The intended outcome of the research is to improve the health and wellbeing of Australians by investing in new clinical trials that support increased access to high-quality, evidence-based and effective health care.

Applicants to this grant opportunity must propose a clinical trial in Australia in collaboration with international counterparts. The clinical trial should not have commenced recruitment at the Australian trial site/s.

Clinical Trials and Cohort Studies Grants

Open Date

9 September 2026

Closing Date

4 November 2026

Grant amount

TBC

Application website

Clinical Trials and Cohort Studies Grants

About

This funding scheme is open to research proposals for clinical trials and/or cohort studies of any size – that is, they may be large or small clinical trials or cohort studies.

The intended outcomes of the Clinical Trials and Cohort Studies Grants scheme are improvements in health and well-being, health care practice or policy, as a result of:

  • High-quality clinical trials that provide reliable evidence of the effects of health-related interventions on health outcomes (or appropriate surrogates).
  • High-quality cohort studies that provide reliable evidence on the relation of important risk factors and other exposures to health-related outcomes.
  • High quality retrospective cohort studies that provide reliable evidence on the relation of important risk factors and other exposures to health-related outcomes.

Partnership Projects 2026 - GO8163

Open Date

7 January 2026

Closing Date

11 November 2026

Grant amount

$1,500,000.00 AUD (Total Amount $35,300,000.00 AUD)

Application website

Partnership Projects 2026

About

Partnership Projects will support collaborations, within the Australian context, that translate research evidence into health policy and health practice, to improve health services and processes.

The objectives of the Partnership Project scheme are to:

• Meet the need for more effective integration of research evidence into health policy and service delivery

• Create partnerships among policy makers, managers, service providers and researchers

• Provide support to answer often complex and difficult questions that policy makers, managers and service providers face when making decisions and implementing policies that affect Australians’ health and health care

• Be highly responsive to the priorities of government, the community and health professionals

• Enable applicants to apply for funding at any time during the year to allow researchers and Partner Organisations to develop timely collaborations.

International Grant Opportunities:

Next Steps Program

Open Date

19 March 2026

Closing Date

10 April 2026 (Letter of Intent); 16 June 2026 (Full Application)

Grant amount

$1,000,000 USD

Application website

Melanoma Research Alliance

About

Through the 2026 Next Steps Program Request for Proposals, Melanoma Research Alliance welcomes proposals that aim to accelerate the development of new approaches and technologies in cellular therapy and vaccine therapy specifically for acral and/or uveal melanoma. Proposals on GNAQ/11 related melanomas are also allowed. This RFP will support preclinical, pre-IND development stage, and clinical-stage studies
focused on advancing cellular or vaccine-based therapeutic approaches that have the potential to
improved treatment strategies for patients with acral or uveal melanoma. Competitive proposals will
demonstrate a clear path toward translating promising preclinical discoveries into near-term clinical
development or clinical trials. It is anticipated that achieving the aims of the proposal may require
the expertise from different departments at a given institution or collaborations across multiple
institutions and core facilities.

Cellular and vaccine therapies include, but are not limited to:

  • CAR T-Cell Therapy
  • Tumor-Infiltrating Lymphocyte (TIL) Therapy
  • T Cell Receptor Therapy
  • Dual Target Cellular Therapy
  • Nucleic Acid or Peptide Personalized Neoantigen or Shared Antigen Vaccines
  • Cell-based Vaccines
  • Oncolytic Virus Vaccines
  • Novel Vaccine Delivery Approaches
  • Combination Approach (e.g., cell therapy and immune or targeted therapy, vaccine therapy and immune or targeted therapy, cell and vaccine combination therapy)

Researchers and clinicians within or outside the U.S. working in academic medical centers, universities, or other non-profit research institutions are eligible to apply.

Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) - PAR-25-167

Open Date

05 January 2025

Closing Date

5 February 2026, 5 June 2026 and 5 October 2026

Grant amount

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Application website

Cancer Prevention and Control Clinical Trials Grant Program

About

This notice of funding opportunity (NOFO) invites applications of investigator-initiated clinical trials (Phase 0-IV) that have the potential to reduce the burden of cancer through improvements in early detection, screening, prevention and interception, healthcare delivery, quality of life, and/or survivorship related to cancer; with such attributes, the proposed studies should also have the potential to improve clinical practice and/or public health. This NOFO does not and will not support clinical trials for studies of cancer diagnosis and/or oncologic therapy in patients.

Examples of relevant areas of research include but are not limited to:

  • Cancer prevention and interception: development and testing of interventions (including diet, nutritional compounds, drugs, small molecules, vaccine and biologics) and approaches (including physical activity, medical devices, cancer preventive surgery, risk-reducing surgery, and non-surgical ablative techniques) to block, reverse, or delay the early stages of cancer (including treatment of preneoplastic lesions and presurgical trials in early stage cancer with the intent of developing an agent/intervention for cancer prevention). This also includes studies examining mechanism and surrogate biomarkers of efficacy;
  • Cancer screening: studies of operating characteristics and clinical impact (harms as well as benefits) of cancer early detection technologies and practices, such as imaging and molecular biomarker approaches;
  • Early detection: studies for identification, development, and validation of biological markers for early cancer detection and cancer risk assessment;
  • Behavioral research in cancer prevention and control: development and testing of interventions addressing risk behaviors such as: tobacco use, energy balance, alcohol use, or sun exposure; vaccine uptake; immune function; screening behavior; treatment adherence; biopsychosocial processes of cancer-related behavior; communication, decision science, environmental modifications and policy changes aimed at altering cancer-related health behaviors and/or preventing or improving cancer-related risks and outcomes;
  • Susceptibility to cancer and cancer-related outcomes: strategies to translate clinical, environmental and genomic/genetic determinants of cancer occurrence and outcomes into evidence-based interventions for clinical and public health practice;
  • Implementation science: strategies to promote the adoption, implementation, and sustainability of evidence-based intervention into routine healthcare and public health settings or the deimplementation of ineffective interventions;
  • Healthcare delivery: single and multi-level interventions addressing the organization and/or delivery of cancer care (e.g., team-based care; novel use of electronic health records; new organizational mechanisms/staffing such as patient navigation; new models of specialized services such as palliative care or survivorship programs);
  • Cancer survivorship: interventions addressing the physical, psychological, social, and financial burden of cancer and its treatment among survivors of cancer and their families (e.g., mental health, social functioning, caregiver well-being and adaptation);
  • Supportive and palliative care: development and testing of interventions (including diet, nutritional compounds, drugs, small molecules, vaccine and biologics) and approaches for the prevention or treatment of acute and chronic symptoms and morbidities related to cancer and its treatment including those experienced by patients with metastatic cancer; and/or
  • Quality of Life (QOL): studies to improve the QOL of patients.
Foreign Organizations
  • Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.
  • Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
  • Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) - PAR-25-081

Open Date

05 January 2025

Closing Date

5 February 2026, 5 June 2026 and 5 October 2026

Grant amount

The total direct costs available is up to: $2,499,995 USD

Application website

National Cancer Institute

About

This notice of funding opportunity (NOFO) is applicable to a broad range of early phase (Phase 0, I, and II) investigator-initiated clinical trial evaluations that improve the diagnosis and treatment of cancer in areas of common and unmet need. Potential areas of research may include, but are not limited to, the clinical evaluation of new or improved anticancer drugs and biologics, including immunotherapies, new or improved imaging technologies and surgical interventions, novel approaches to radiation therapy, and incorporation of complementary and alternative medicine approaches to treatment. The research component may include the development of therapeutics, diagnostics, and devices in combination with standard care therapies including chemotherapy, immunotherapy, surgery, radiotherapy, or any combination of these modalities. Additional research aims can be proposed as part of the overall research plan provided it includes at least 1 clinical trial to be completed within the project period.

Note that Phase III clinical trials will not be accepted through this NOFO.

Description of the type of clinical trials that can be supported include:

  • Single-site clinical trial(s): Early phase trials where the protocol is implemented by one investigational site that conducts and coordinates the protocol. While a single-site clinical trial may enroll participants from multiple locations/clinics within a geographic area, those participants will receive an intervention or undergo outcome assessments under the direction and oversight of one research team at one investigational site.
  • Multi-site clinical trial(s): Early phase trials that recruit study subjects from two or more geographically distinct enrollment sites, or centers. The sites are usually distinct in other characteristics (e.g., demographic, socioeconomic, or clinical). Study protocols are followed at these sites.
  • Mechanistic clinical trial(s): Hypothesis-driven interventional studies (i.e., early phase trials) focused on basic and/or translational, discovery research on the biology and pathophysiology of cancer or the mechanism of action of an intervention.
  • Feasibility clinical trial(s): Early phase trials that propose to break new ground and/or extend previous discoveries toward new directions and/or applications.
  • Pragmatic trial(s): Early phase trials that test an intervention under the usual clinical conditions in which it will be applied, while explanatory trials do so under more idealized circumstances.
  • Ancillary clinical trial(s): Early phase trials that address research questions related to ongoing trials but are distinct from the primary/secondary objectives of the parent study. An ancillary clinical trial is an independent trial that includes an additional intervention prospectively assigned to patients or a subpopulation of patients within a larger trial. For helpful examples, see case studies 42b and 42c.
  • Pharmacodynamic trial(s): Early phase trials that link outcomes to measurements on pre- and post-treatment specimens to test hypotheses about therapeutic mechanisms based on pre-clinical data.
  • Biomarker-driven trial(s): Early phase trials that test predictive or prognostic biomarker findings obtained from pilot trials.
  • Co-clinical trial(s): Early phase trials that involve patients and in parallel (or sequentially) animal or human-in-animal models of cancer that mirror the genetics and biology of the patients’ malignancies or pre-cancerous lesions. The co-clinical trial should include either a therapeutic goal (e.g., the prediction, staging, and/or measurement of tumor response to therapies) or an early diagnostic goal.
Foreign Organizations
  • Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.
  • Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
  • Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required) - RFA-FD-25-020

Open Date

22 August 2025

Closing Date

20 October 2026 and 19 October 2027

Grant amount

The total funds available is up to: $2,600,000 USD

Application website

Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases

About

This grant is intended to support clinical trials of orphan products in all phases of product development (phase 1, 2 and/or 3) for rare diseases with unmet medical needs. These clinical trials should evaluate safety and/or efficacy of medical products in support of a new indication or a change in labeling. Depending on the phase of development, these trials may need to include an appropriate comparator, such as a placebo, a concurrent external control, or a historical control.  Applicants are encouraged to refer to “Rare Diseases: Considerations for the Development of Drugs and Biological Products” for guidance on conducting more efficient and successful drug development programs. Applicants are also encouraged to refer to Guidance Documents for Rare Disease Drug Development for selected guidances relevant to rare disease drug development and information on the Orphan Products Grants Program website before applying for this opportunity.

To facilitate efficient product development, the use of shared, established infrastructure and resources and collaborative efforts between stakeholders in industry, academia, and patient organizations are highly encouraged under this grant. Additionally, patients living with a rare disease, or their caregivers have experiences and knowledge that contribute to important considerations in product development, such as with trial feasibility, thus early and ongoing patient engagement is also highly encouraged.

Innovative and Efficient Trial Approaches:
FDA is interested in supporting innovative and efficient trial designs and will allow for additional funding with justification for applications proposing the use of one or more of the following:

  • Innovative trial designs such as seamless and adaptive trial designs, which compress the phases of a trial into one continuous trial, as well as basket, umbrella and platform trials, which allow for testing of multiple drugs and/or multiple diseases using a common infrastructure.
  • Innovative methods using data simulations and modeling toward the study of safety and efficacy of a product.

These approaches may hold significant promise for the advancement of therapeutic treatments for rare diseases through all phases of product development. Early engagement with FDA review divisions to discuss the use of these innovative approaches is highly recommended prior to submitting a grant application (e.g., preIND, INTERACT, other meetings).

Foreign Organizations
  • Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.
  • Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
  • Foreign components, as defined in the NIH Grants Policy Statement, are allowed.